Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus

Virology

Volumn 351, Issue 1, 2006, Pages 133-144

  Kuate, Seraphin ^a   Stahl Hennig, Christiane ^b   Stoiber, Heribert ^c   Nchinda, Godwin ^a,d   Floto, Anja ^b   Franz, Monika ^b   Sauermann, Ulrike ^b   Bredl, Simon ^e   Deml, Ludwig ^e   Ignatius, Ralf ^f   Norley, Steve ^g   Racz, Paul ^h   Tenner Racz, Klara ^h   Steinman, Ralph M ^d   Wagner, Ralf ^e   Überla, Klaus ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b GERMAN PRIMATE CENTER   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d ROCKEFELLER UNIVERSITY   (United States)

^e UNIVERSITY OF REGENSBURG   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g ROBERT KOCH INSTITUTE   (Germany)

^h BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

Author keywords

HIV; Immunization; SIV; Vaccine; VLP

Indexed keywords

DNA VACCINE; GAG PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VACCINATION; VESICULAR STOMATITIS VIRUS; VIREMIA; VIRUS LOAD; VIRUS PARTICLE; VIRUS TYPING;

AIDS VACCINES; ANIMALS; CELL LINE; DRUG ADMINISTRATION SCHEDULE; HIV ANTIBODIES; HUMANS; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; MICE; RNA, VIRAL; TIME FACTORS; VESICULAR STOMATITIS-INDIANA VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIRION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; PRIMATES; SIMIAN IMMUNODEFICIENCY VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 33745863446     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.03.009     Document Type: Article

References (39)

1. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.L., Grimm B.D., Hulsey M.L., Miller J., McClure H.M., McNicholl J.M., Moss B., and Robinson H.L. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 (2001) 69-74
2. Arthur L.O., Bess Jr. J.W., Chertova E.N., Rossio J.L., Esser M.T., Benveniste R.E., Henderson L.E., and Lifson J.D. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. AIDS Res. Hum. Retroviruses 14 Suppl. 3 (1998) S311-S319
3. Burns J.C., Friedmann T., Driever W., Burrascano M., and Yee J.K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 8033-8037
4. Chackerian B., Haigwood N.L., and Overbaugh J. Characterization of a CD4-expressing macaque cell line that can detect virus after a single replication cycle and can be infected by diverse simian immunodeficiency virus isolates. Virology 213 (1995) 386-394
5. Daniel M.D., Kirchhoff F., Czajak S.C., Sehgal P.K., and Desrosiers R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258 (1992) 1938-1941
6. Deml L., Schirmbeck R., Reimann J., Wolf H., and Wagner R. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Virology 235 (1997) 26-39
7. Desrosiers R.C. Prospects for an AIDS vaccine. Nat. Med. 10 (2004) 221-223
8. Evans D.T., Bricker J.E., and Desrosiers R.C. A novel approach for producing lentiviruses that are limited to a single cycle of infection. J. Virol. 78 (2004) 11715-11725
9. Evans D.T., Bricker J.E., Sanford H.B., Lang S., Carville A., Richardson B.A., Piatak Jr. M., Lifson J.D., Mansfield K.G., and Desrosiers R.C. Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239. J. Virol. 79 (2005) 7707-7720
10. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., and Para M.F. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191 (2005) 654-665
11. Giavedoni L.D., Planelles V., Haigwood N.L., Ahmad S., Kluge J.D., Marthas M.L., Gardner M.B., Luciw P.A., and Yilma T.D. Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J. Virol. 67 (1993) 577-583
12. Granelli-Piperno A., Zhong L., Haslett P., Jacobson J., and Steinman R.M. Dendritic cells, infected with vesicular stomatitis virus-pseudotyped HIV-1, present viral antigens to CD4+ and CD8+ T cells from HIV-1-infected individuals. J. Immunol. 165 (2000) 6620-6626
13. Gundlach B.R., Reiprich S., Sopper S., Means R.E., Dittmer U., Matz-Rensing K., Stahl-Hennig C., and Überla K. Env-independent protection induced by live, attenuated simian immunodeficiency virus vaccines. J. Virol. 72 (1998) 7846-7851
14. Hansen A.C., Grunwald T., Lund A.H., Schmitz A., Duch M., Überla K., and Pedersen F.S. Transfer of primer binding site-mutated simian immunodeficiency virus vectors by genetically engineered artificial and hybrid tRNA-like primers. J. Virol. 75 (2001) 4922-4928
15. Helseth E., Kowalski M., Gabuzda D., Olshevsky U., Haseltine W., and Sodroski J. Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants. J. Virol. 64 (1990) 2416-2420
16. Hofmann-Lehmann R., Williams A.L., Swenerton R.K., Li P.L., Rasmussen R.A., Chenine A.L., and Ruprecht R.M. Quantitation of simian cytokine and beta-chemokine mRNAs, using real-time reverse transcriptase-polymerase chain reaction: variations in expression during chronic primate lentivirus infection. AIDS Res. Hum. Retroviruses 18 (2002) 627-639
17. Horton H., Vogel T.U., Carter D.K., Vielhuber K., Fuller D.H., Shipley T., Fuller J.T., Kunstman K.J., Sutter G., Montefiori D.C., Erfle V., Desrosiers R.C., Wilson N., Picker L.J., Wolinsky S.M., Wang C., Allison D.B., and Watkins D.I. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J. Virol. 76 (2002) 7187-7202
18. Johnson R.P. Mechanisms of protection against simian immunodeficiency virus infection. Vaccine 20 (2002) 1985-1987
19. Kuate S., Stahl-Hennig C., Haaft P.T., Heeney J., and Überla K. Single cycle immunodeficiency viruses provide strategies for uncoupling in vivo expression levels from viral replicative capacity and for mimicking live attenuated SIV vaccines. Virology 313 (2003) 653-662
20. Le Grand R., Vogt G., Vaslin B., Roques P., Theodoro F., Aubertin A.M., and Dormont D. Specific and non-specific immunity and protection of macaques against SIV infection. Vaccine 10 (1992) 873-879
21. Lifson J.D., Piatak Jr. M., Rossio J.L., Bess Jr. J., Chertova E., Schneider D., Kiser R., Coalter V., Poore B., Imming R., Desrosiers R.C., Henderson L.E., and Arthur L.O. Whole inactivated SIV virion vaccines with functional envelope glycoproteins: safety, immunogenicity, and activity against intrarectal challenge. J. Med. Primatol. 31 (2002) 205-216
22. Lu X., Kiyono H., Lu D., Kawabata S., Torten J., Srinivasan S., Dailey P.J., McGhee J.R., Lehner T., and Miller C.J. Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251. AIDS 12 (1998) 1-10
23. Malim M.H., Hauber J., Fenrick R., and Cullen B.R. Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. Nature 335 (1988) 181-183
24. Marsac D., Loirat D., Petit C., Schwartz O., and Michel M.L. Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles. J. Virol. 76 (2002) 7544-7553
25. Marthas M.L., Sutjipto S., Higgins J., Lohman B., Torten J., Luciw P.A., Marx P.A., and Pedersen N.C. Immunization with a live, attenuated simian immunodeficiency virus (SIV) prevents early disease but not infection in rhesus macaques challenged with pathogenic SIV. J. Virol. 64 (1990) 3694-3700
26. Murphy C.G., Lucas W.T., Means R.E., Czajak S., Hale C.L., Lifson J.D., Kaur A., Johnson R.P., Knipe D.M., and Desrosiers R.C. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J. Virol. 74 (2000) 7745-7754
27. Nchinda G., Zschörnig O., and Überla K. Increased non-viral gene transfer levels in mice by concentration of cationic lipid DNA complexes formed under optimized conditions. J. Gene Med. 5 (2003) 712-722
28. Notka F., Stahl-Hennig C., Dittmer U., Wolf H., and Wagner R. Accelerated clearance of SHIV in rhesus monkeys by virus-like particle vaccines is dependent on induction of neutralizing antibodies. Vaccine 18 (1999) 291-301
29. Paliard X., Liu Y., Wagner R., Wolf H., Baenziger J., and Walker C.M. Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res. Hum. Retroviruses 16 (2000) 273-282
30. Puffer B.A., Pohlmann S., Edinger A.L., Carlin D., Sanchez M.D., Reitter J., Watry D.D., Fox H.S., Desrosiers R.C., and Doms R.W. CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J. Virol. 76 (2002) 2595-2605
31. Stahl-Hennig C., Herchenröder O., Nick S., Evers M., Stille-Siegener M., Jentsch K.D., Kirchhoff F., Tolle T., Gatesman T.J., Lüke W., and Hunsmann G. Experimental infection of macaques with HIV-2ben, a novel HIV-2 isolate. AIDS 4 (1990) 611-617
32. Stahl-Hennig C., Steinman R.M., Tenner-Racz K., Pope M., Stolte N., Matz-Rensing K., Grobschupff G., Raschdorff B., Hunsmann G., and Racz P. Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science 285 (1999) 1261-1265
33. Stahl-Hennig C., Steinman R.M., ten Haaft P., Uberla K., Stolte N., Saeland S., Tenner-Racz K., and Racz P. The simian immunodeficiency virus deltaNef vaccine, after application to the tonsils of Rhesus macaques, replicates primarily within CD4(+) T cells and elicits a local perforin-positive CD8(+) T-cell response. J. Virol. 76 (2002) 688-696
34. Stott E.J. Anti-cell antibody in macaques. Nature 353 (1991) 393
35. Tenner-Racz K., Hennig C.S., Uberla K., Stoiber H., Ignatius R., Heeney J., Steinman R.M., and Racz P. Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 3017-3022
36. Wagner R., Graf M., Bieler K., Wolf H., Grunwald T., Foley P., and Überla K. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum. Gene Ther. 11 (2000) 2403-2413
37. Wang S.W., Kozlowski P.A., Schmelz G., Manson K., Wyand M.S., Glickman R., Montefiori D., Lifson J.D., Johnson R.P., Neutra M.R., and Aldovini A. Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions. J. Virol. 74 (2000) 10514-10522
38. Whitt M.A., Zagouras P., Crise B., and Rose J.K. A fusion-defective mutant of the vesicular stomatitis virus glycoprotein. J. Virol. 64 (1990) 4907-4913
39. Wild J., Bojak A., Deml L., and Wagner R. Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model. Vaccine 22 (2004) 1732-1743